The big question in suicide prevention is how we can reach people at risk who would not normally seek professional help.
RPT904 at both Q8W and Q12W dosing showed comparable efficacy and safety to omalizumab at Q4W dosing - Efficacy sustained at Week 16 after a single dose of RPT904 - Well tolerated with no serious ...
At the 2025 European Society for Medical Oncology (ESMO) Congress, a Phase III clinical study on disitamab vedotin plus toripalimab versus chemotherapy as first-line treatment for HER2-expressing loca ...
Topline data were announced from two phase 3 trials evaluating orforglipron, an oral GLP-1 receptor agonist, in patients with type 2 diabetes.
Event-free survival (EFS) improved by 60% and overall survival (OS) by 50% with the antibody-drug conjugate (ADC) enfortumab vedotin (Padcev) plus pembrolizumab (Keytruda) versus upfront radical ...
Across several clinical outcomes, including 28-day mortality, beta-blocker esmolol was more effective than standard care and ...
A groundbreaking study reveals that cancer patients who received a COVID-19 mRNA vaccine within 100 days of starting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback